Publication: Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update
Issued Date
2018-04-01
Resource Type
ISSN
15326535
00099236
00099236
DOI
Other identifier(s)
2-s2.0-85041319988
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Pharmacology and Therapeutics. Vol.103, No.4 (2018), 574-581
Suggested Citation
Elizabeth J. Phillips, Chonlaphat Sukasem, Michelle Whirl-Carrillo, Daniel J. Müller, Henry M. Dunnenberger, Wasun Chantratita, Barry Goldspiel, Yuan Tsong Chen, Bruce C. Carleton, Alfred L. George, Taisei Mushiroda, Teri Klein, Roseann S. Gammal, Munir Pirmohamed Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clinical Pharmacology and Therapeutics. Vol.103, No.4 (2018), 574-581. doi:10.1002/cpt.1004 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46818
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update
Other Contributor(s)
Duke University Medical Center
NorthShore University HealthSystem
Vanderbilt University Medical Center
University of Liverpool
St. Jude Children's Research Hospital
Academia Sinica Taiwan
University of Toronto
Riken
NIH Clinical Center
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Centre for Addiction and Mental Health
Northwestern University Feinberg School of Medicine
Stanford University
The University of British Columbia
MCPHS University
NorthShore University HealthSystem
Vanderbilt University Medical Center
University of Liverpool
St. Jude Children's Research Hospital
Academia Sinica Taiwan
University of Toronto
Riken
NIH Clinical Center
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Centre for Addiction and Mental Health
Northwestern University Feinberg School of Medicine
Stanford University
The University of British Columbia
MCPHS University
Abstract
© 2018 American Society for Clinical Pharmacology and Therapeutics The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.